A new oral testosterone undecanoate formulation

@article{Khn2003ANO,
  title={A new oral testosterone undecanoate formulation},
  author={Frank Michael K{\"o}hn and Wolf Bernhard Schill},
  journal={World Journal of Urology},
  year={2003},
  volume={21},
  pages={311-315}
}
  • F. Köhn, W. Schill
  • Published 25 October 2003
  • Medicine, Biology
  • World Journal of Urology
Testosterone undecanoate has been available on the market for more than 20 years. This testosterone ester is used worldwide for oral treatment of male hypogonadism. So far, testosterone undecanoate has been dissolved in oleic acid, leading to inconvenient storage conditions. It will now be available in a new formulation with castor oil and propylene glycol laurate instead of oleic acid, thus improving storage conditions markedly (stable at room temperature for approximately 3 years… 
Testosterone Therapy: Oral Androgens
TLDR
Taking into account a lower requirement of testosterone in women as compared to men, oral testosterone undecanoate can be effectively adapted for use in women based on the clinical indication of testosterone deficiency and response to therapy.
An oral lipidic native testosterone formulation that is absorbed independent of food
TLDR
This formulation, DITEST, has the potential advantage of being oral for patients who do not tolerate injections and less risk of adverse events that might theoretically be associated with elevated dihydrotestosterone levels.
The Current Status ofTherapy for Symptomatic Late-Onset HypogonadismwithTransdermalTestosterone Gel
TLDR
The first 3–6 months after initiating testosterone therapy is the most critical time for monitoring effects on the prostate, so it is important to monitor PSA levels every 3 months for the first year of treatment; thereafter, regular monitoring (mostly for prostate safety but also for cardiovascular and haematological safety) during therapy is mandatory.
Comparison of oral versus transdermal testosterone supplementation in hypogonadal men
TLDR
Testopatch was superior to Pantestone to increase testosterone and bioavailable-testosterone levels in hypogonadal men from the first days and throughout the three weeks of treatment.
Production and characterization of testosterone undecanoate-loaded NLC for oral bioavailability enhancement
TLDR
From the perspective of administering a single dose of dose of TU in one oral dosage unit and simultaneously having a bioavailability less dependent on the fed state, a direct comparison of the size effect in in vivo bioavailability studies is opened.
Complications of injectable testosterone undecanoate in routine clinical practice.
TLDR
TU injections produce a low incidence of POME with injections by experienced nurses, but recurrence is more frequent than by chance, and polycythaemia was a minor problem rarely requiring treatment other than optimising inter-injection interval.
Profile of serum testosterone levels after application of testosterone ointment (glowmin) and its clinical efficacy in late-onset hypogonadism patients.
TLDR
After 12 weeks of GL treatment in 50 LOH patients, TT and FT levels demonstrated the same satisfactory response as that of the initial GL administration without GL accumulation effects, and GL appears to be suitable for LOH treatment.
Effectiveness of a low dose testosterone undecanoate to improve sexual function in postmenopausal women
TLDR
The twice weekly addition of testosterone undecanoate to daily oral estrogen was associated with a significant improvement in sexual function among postmenopausal women than the use of the estrogen alone.
Clinical experience with Andriol® Testocaps®– The first Austrian surveillance study on the treatment of late-onset hypogonadism
  • A. Jungwirth, E. Plas, P. Geurts
  • Medicine
    The aging male : the official journal of the International Society for the Study of the Aging Male
  • 2007
TLDR
Short-term treatment with oral testosterone undecanoate in a clinical practice setting improved late-onset hypogonadism symptoms in aging men with low testosterone levels.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
A ten-year safety study of the oral androgen testosterone undecanoate.
  • L. Gooren
  • Medicine, Biology
    Journal of andrology
  • 1994
TLDR
Testosterone undecanoate appears to be a safe oral androgen that provides the hypogonadal patient with the unmodified testosterone molecule and a yearly checkup of the patient on therapy with this androgen seems adequate.
Oral testosterone undecanoate (Andriol®) supplement therapy improves the quality of life for men with testosterone deficiency
  • N. Park, B. Yan, J. Chung, K. M. Lee
  • Medicine, Biology
    The aging male : the official journal of the International Society for the Study of the Aging Male
  • 2003
TLDR
It is concluded that androgen supplement therapy with oral testosterone undecanoate (Andriol) restores the quality of life through improvement of general body functions in men with testosterone deficiency.
Trial of high-dose testosterone undecanoate in treatment of male infertility.
TLDR
The preliminary data suggest that although complete suppression of spermatogenesis is not uniformly achieved, a controlled study on the effects of high doses of testosterone undecanoate in male infertility may now by warranted.
Randomized clinical trial of testosterone replacement therapy in hypogonadal men.
TLDR
Testosterone pellets give the closest approximation to zero-order delivery conditions for up to 4 months after a single insertion, which suggests that the liver is exposed to excessive androgenic load via the portal vein during oral treatment with testosterone esters.
Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men.
TLDR
The study shows that testosterone undecanoate is well absorbed from the gut and releases significantly elevated amounts of testosterone which is available to target tissues.
Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo controlled study.
TLDR
It is concluded that TU may be an effective drug for protecting coronary heart disease in healthy elderly men with lowered TT and FT levels and may also have beneficial effects for sexual function and behavior.
Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume.
TLDR
It is suggested that exogenous testosterone in middle-aged and older men with some clinical features of age-related androgen deficiency can retard or reverse prostate growth and that elevated plasma LH may be a useful index of severity ofAge-relatedandrogen deficiency.
Contribution of Lymphatically Transported Testosterone Undecanoate to the Systemic Exposure of Testosterone after Oral Administration of Two Andriol Formulations in Conscious Lymph Duct-Cannulated Dogs
TLDR
Stable isotope methodology in a thoracic lymph duct-cannulated dog model demonstrates that intestinal lymphatic transport of TU produces increased systemic exposure of T by avoiding the extensive first-pass effect responsible for the inactivation of T after oral administration.
Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth.
TLDR
It is suggested that oral TU is a well accepted, effective, and safe treatment for the initiation of male puberty without disproportionate skeletal maturation and continued pubertal advance was evident after cessation of treatment in all patients.
...
1
2
3
4
5
...